Optimization of metabolic stability as a goal of modern drug design

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Medicinal research reviews (Print)

• Publication date

  2001-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/med.1017PMID 11579441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective

  2004cited by this paper
• Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development.

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• High-throughput high-performance liquid chromatography/mass spectrometry for modern drug discovery.

  2001cited by this paper
• Computational methods for the prediction of 'drug-likeness'

  2000cited by this paper
• On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.

  2000cited by this paper
• Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles.

  2000cited by this paper
• Early ADME in support of drug discovery: the role of metabolic stability studies.

  2000influential reference
• Predicting Human Oral Bioavailability of a Compound: Development of a Novel Quantitative Structure-Bioavailability Relationship

  2000cited by this paper
• QSAR model for drug human oral bioavailability.

  2000cited by this paper
• Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance.

  2000cited by this paper
• High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.

  2000cited by this paper
• QSAR Model for Drug Human Oral Bioavailability1

  2000cited by this paper
• Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability.

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Advances in in vitro drug metabolism screening

  1999cited by this paper
• A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.

  1999cited by this paper
• Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4.

  1999cited by this paper
• Use and value of metabolism databases.

  1999cited by this paper
• Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.

  1999cited by this paper
• Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.

  1999cited by this paper
• Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.

  1999cited by this paper
• Advances in drug metabolism screening.

  1999cited by this paper
• Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.

  1999cited by this paper
• Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication.

  1999cited by this paper
• Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations

  1999cited by this paper
• In vitro stability and intestinal absorption characteristics of hexapeptide endothelin receptor antagonists.

  1998cited by this paper
• Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism.

  1998cited by this paper
• Isoindol-1-one analogues of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridyl)-p-iodobenzamido]ethyl]pipera zine (p-MPPI) as 5-HT1A receptor ligands.

  1998cited by this paper
• Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.

  1998cited by this paper
• Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

  1998cited by this paper
• Metabolic screening using on-line ultrafiltration mass spectrometry.

  1998cited by this paper
• Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.

  1998cited by this paper
• High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds.

  1998cited by this paper
• Discovery of bioavailable inhibitors of secretory phospholipase A2.

  1998cited by this paper
• Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

  1998cited by this paper
• Development of Orally Active Oxytocin Antagonists: Studies on 1‐(1‐{4‐[1‐(2‐Methyl‐1‐oxidopyridin‐3‐ylmethyl)piperidin‐4‐yloxy] ‐2‐methoxybenzoyl}piperidin‐4‐yl)‐1,4‐dihydrobenz[d][1,3]oxazin‐2‐one (L‐372,662) and Related Pyridines.

  1998cited by this paper
• Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.

  1997cited by this paper
• Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.

  1997cited by this paper
• Synthetic strategies to lower affinity for CYP2D6

  1997cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.

  1997cited by this paper
• Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective.

  1997cited by this paper
• Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

  1997cited by this paper
• Role of Pharmacokinetics and Metabolism in Drug Discovery and Development

  1997cited by this paper
• Role of pharmacokinetics and metabolism in drug discovery and development.

  1997cited by this paper
• Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics

  1997cited by this paper
• Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates

  1997cited by this paper
• Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists

  1997cited by this paper
• HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process

  1997cited by this paper
• Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.

  1997cited by this paper
• Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.

  1997cited by this paper
• Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs.

  1996cited by this paper
• Drug discovery and drug metabolism

  1996cited by this paper
• Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

  1996cited by this paper
• Predicting the regioselectivity and stereoselectivity of cytochrome P450-mediated reactions: structural models for bioactivation reactions.

  1996cited by this paper
• Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).

  1996cited by this paper
• An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials

  1996cited by this paper
• Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

  1996cited by this paper
• Electrochemiluminescence-Based Quantitation of Classical Clinical Chemistry Analytes

  1996cited by this paper
• Electronic models for cytochrome P450 oxidations.

  1996cited by this paper
• The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies

  1995cited by this paper
• Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

  1994cited by this paper
• Design of drugs through a consideration of drug metabolism and pharmacokinetics

  1994cited by this paper
• Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of alpha-naphthol, beta-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases.

  1993cited by this paper
• The use of in vitro metabolism studies in the understanding of new drugs.

  1993cited by this paper
• Quantitative structure-activity relationships of cytochrome P-450.

  1993cited by this paper
• Role of metabolism and pharmacokinetic studies in the discovery of new drugs--present and future perspectives.

  1992cited by this paper
• Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.

  1992cited by this paper
• Mechanisms of cytochrome P‐450 catalysis

  1990cited by this paper
• Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).

  1988cited by this paper
• Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.

  1977cited by this paper

• A Heterometallic Metal-Organic Framework with Atomically Precise Single-Cu Sites for Photocatalysis.

  2026cites this paper
• Dual inhibition of ERG11 and CDR2 in drug-resistant Candida albicans by Indian phytochemicals: a combined in silico–in vitro approach

  2026cites this paper
• Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: in vitro and in silico metabolic stability assessment.

  2026cites this paper
• A hydrophilic interaction UPLC-MS/MS quantitative method for the quantification of saracatinib in the human liver microsome matrix and its application in in vitro metabolic stability assessment.

  2026cites this paper
• Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability.

  2026cites this paper
• Structure-guided design and synthesis of selective butyrylcholinesterase inhibitors

  2026cites this paper
• Assessment of Apalutamide Metabolic Stability in HLMs Matrix Using a Sensitive and Fast UPLC-MS/MS Method: In Silico Screening for Toxicity Alerts and Metabolic Lability.

  2026cites this paper
• Photocatalytic Copper-Mediated Functionalization of Aryl Iodides with Fluoride and Water

  2025cites this paper
• Dose-dependent modulation of hepatic cytochrome P450 enzymes by tenvermectin: implications for medication safety and combination therapy

  2025cites this paper
• Identification of Substituted 4-Aminocinnolines as Broad-Spectrum Antiparasitic Agents

  2025cites this paper
• Exploring a series of multifunctional Mn(I) tricarbonyls as prospective agents against trypanosomatid parasites: a comparative study with the Re(I) analogues.

  2025cites this paper
• Deuteration Strategy-Inspired Design of Novel Diarylpyrimidine Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Efficacy, Selectivity, and Druggability.

  2025cites this paper
• A review on polymer micelles as drug carriers

  2025cites this paper
• iDILI-MT: identifying drug-induced liver injury compounds with a multi-head Transformer

  2025cites this paper
• Evaluating indole‑gold(I) based complexes as potential anti lymphoma agents by disrupting the thioredoxin reductase/glutathione peroxidase axis.

  2025cites this paper
• MetaboGNN: predicting liver metabolic stability with graph neural networks and cross-species data

  2025cites this paper
• Novel Diaryl-Substituted Pyrazolo[3,4-d]pyrimidines as Tubulin/CDC5L Dual-Targeting Ligands: Discovery, Potent Antitumor Activity, and Good Metabolic Stability.

  2025cites this paper
• Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability.

  2025cites this paper
• Evaluation of Niraparib Metabolic Stability in Human Liver Microsomes Using Ultrafast UPLC-MS/MS Technique: In Silico Screening for Structural Alerts Related to the Metabolic Lability and In Silico DEREK Toxicity.

  2025cites this paper
• F-Site: Recognizing Fluorination Patterns in Small-Molecule Drugs via a Two-Stage Transformer-Based Model

  2025cites this paper
• Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction.

  2025cites this paper
• Assessment of the metabolic stability of avapritinib in human liver microsomes using a fast and green UPLC-MS/MS method: screening for structural alarms associated with metabolic lability and in silico toxicity.

  2025cites this paper
• Evaluation on the Potential for Hepatotoxic Components from Herba Epimedii to Induce Apoptosis in HepG2 Cells and the Analysis of the Influence of Metabolism in Liver Microsomes

  2024cites this paper
• Recent developments on the synthesis of biologically active glycohybrids.

  2024cites this paper
• The Structure-property Relationships of Clinically Approved Protease Inhibitors.

  2023cites this paper
• Copper-Catalyzed Benzylic C-H Cross-Coupling Enabled by Redox Buffers: Expanding Synthetic Access to Three-Dimensional Chemical Space.

  2023cites this paper
• INTEDE 2.0: the metabolic roadmap of drugs

  2023cites this paper
• A computational approach to identify novel plant metabolites against Aspergillus fumigatus

  2023cites this paper
• Synthesis and evaluation of a novel PET ligand, a GSK’963 analog, aiming at autoradiography and imaging of the receptor interacting protein kinase 1 in the brain

  2023cites this paper
• Metal-free photoinduced C(sp3)–H/C(sp3)–H cross-coupling to access α‑tertiary amino acid derivatives

  2023cites this paper
• Investigation of plant metabolites as potential inhibitors of Acinetobacter baumannii: An In-Silico approach

  2023cites this paper
• Iron-Catalyzed Oxidative Etherification of Benzylic C(sp3)–H Bonds with Phenols

  2023cites this paper
• Robust late-stage benzylic C(sp3)–H aminations by using transition metal-free photoredox catalysis

  2023cites this paper
• Multifunctional organometallic compounds for the treatment of Chagas disease: Re(I) tricarbonyl compounds with two different bioactive ligands.

  2023cites this paper
• Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids

  2022cites this paper
• Generation of new inhibitors of selected cytochrome P450 subtypes– In silico study

  2022cites this paper
• Transition metal-free approach for late-stage benzylic C(sp3)-H etherifications and esterifications.

  2022cites this paper
• Structural insights into the design of reversible fluorescent probes for metallo-β-lactamases NDM-1, VIM-2, and IMP-1.

  2022cites this paper
• Easy-to-Implement Hydrogen Isotope Exchange for the Labeling of N-Heterocycles, Alkylkamines, Benzylic Scaffolds, and Pharmaceuticals

  2022cites this paper
• Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

  2022cites this paper
• Selectfluor-Enabled C(sp3)-H Alkoxylation of 3-Methylfuranocoumarins.

  2021cites this paper
• In vitro ADME and in vivo pharmacokinetics

  2021cites this paper
• A Catalyst/Oxidant/Base Free Benzylic Csp 3 −H Alkoxylation of toluidines via Electro‐oxidative Csp 3 −O‐Coupling with Alcohols

  2021cites this paper
• How can SHAP values help to shape metabolic stability of chemical compounds?

  2021cites this paper
• Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals.

  2021cites this paper
• The influence of phase II enzymes on in vitro half-life of pirydo[1,2-c]pirymidine derivatives as structural analogues of arylpiperazine

  2020cites this paper
• In vivo efficacy and metabolism of the antimalarial 1 cycleanine and improved in vitro antiplasmodial 2 activity of novel semisynthetic analogues 3

  2020cites this paper
• In Vivo Efficacy and Metabolism of the Antimalarial Cycleanine and Improved In Vitro Antiplasmodial Activity of Semisynthetic Analogues

  2020cites this paper
• Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.

  2020cites this paper
• Site-selective, catalytic, and diastereoselective sp3 C–H hydroxylation and alkoxylation of vicinally functionalized lactams

  2020cites this paper
• Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography–Mass Spectrometric Method

  2020cites this paper
• Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis.

  2020cites this paper
• A tutorial for the assessment of the stability of organometallic complexes in biological media

  2020cites this paper
• Copper-catalysed benzylic C–H coupling with alcohols via radical relay enabled by redox buffering

  2020cites this paper
• Copper-Catalyzed Benzylic C–H Coupling with Alcohols via Radical Relay

  2019cites this paper
• Metabolic stability and its role in the discovery of new chemical entities

  2019cites this paper
• Fluorination patterns in small alkyl groups

  2019cites this paper
• Synthesis of Benzylic Alcohols by C–H Oxidation

  2019cites this paper
• Recent Achievements in Medicinal and Supramolecular Chemistry of Betulinic Acid and Its Derivatives

  2019cites this paper
• Design und Synthese neuer TGFβ-Inhibitoren zur Regeneration von Herzmuskelgewebe

  2019influential citation
• Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.

  2018cites this paper
• Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.

  2018cites this paper
• Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand.

  2018cites this paper
• MetStabOn—Online Platform for Metabolic Stability Predictions

  2018cites this paper
• Dissociative protonation and long-range proton migration: The chemistry of singly- and doubly-protonated tigecycline

  2018cites this paper
• Partially fluorinated alkoxy groups − Conformational adaptors to changing environments

  2017cites this paper
• Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors.

  2017cites this paper
• Synthesis, Biological Activity and Preliminary in Silico ADMET Screening of Polyamine Conjugates with Bicyclic Systems

  2017cites this paper
• Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide.

  2017cites this paper
• The Isoxazole Ring and Its N‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics

  2017cites this paper
• Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.

  2017cites this paper
• The role of intramolecular self‐destruction of reactive metabolic intermediates in determining toxicity

  2016cites this paper
• Effect of Partially Fluorinated N‐Alkyl‐Substituted Piperidine‐2‐carboxamides on Pharmacologically Relevant Properties

  2016cites this paper
• Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.

  2016cites this paper
• Investigations of Bi-phasic Drug Depletion in Liver Microsomes and Hepatocytes in Metabolic Stability Studies

  2015cites this paper
• Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites

  2015cites this paper
• Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.

  2015cites this paper
• Discovery of novel purine-based heterocyclic P2X7 receptor antagonists.

  2015cites this paper
• Chapter 6 – In vitro ADME and In vivo Pharmacokinetics

  2015cites this paper
• Metabolic Assessment in Alamethicin-Activated Liver Microsomes: Co-activating CYPs and UGTs

  2014cites this paper
• Drug Metabolism in Early Stage Drug Discovery and Drug Development

  2014cites this paper
• Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.

  2014cites this paper
• Pharmacokinetics, Metabolism and Excretion of Hypolipidemic DRUG: 16-Dehydropregnenolone

  2013cites this paper
• Drug Metabolism & Toxicology

  2013cites this paper
• Design and synthesis of the stabilized analogs of belactosin A with the unnatural cis-cyclopropane structure.

  2013cites this paper
• Drug Interaction Assessment Strategies: Small Molecules versus Therapeutic Proteins

  2013cites this paper
• Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.

  2013cites this paper
• 先导化合物结构优化策略（一）——改变代谢途径提高代谢稳定性

  2013cites this paper
• Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle.

  2012cites this paper
• In Vitro ADME Profiling and Pharmacokinetic Screening in Drug Discovery

  2012cites this paper
• Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4.

  2012cites this paper
• Fyn Inhibition by Cycloalkane-Fused 1,2-Dithiole-3-thiones Enhances Antioxidant Capacity and Protects Mitochondria from Oxidative Injury

  2012cites this paper
• Mitigating heterocycle metabolism in drug discovery.

  2012cites this paper
• Evaluation of an accurate mass approach for the simultaneous detection of drug and metabolite distributions via whole-body mass spectrometric imaging.

  2012cites this paper
• A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes.

  2012cites this paper
• Quantitative in Vitro ADME Assays Using LC–MS as a Part of Early Drug Metabolism Screening

  2011cites this paper
• Nanosized drug formulations under microfluidic continuous flow.

  2011cites this paper
• Drug Metabolism Research as Integral Part of Drug Discovery and Development Processes

  2011cites this paper
• Pharmacokinetic and pharmacodynamic studies of a novel spectinamide series of antituberculosis agents

  2011cites this paper
• Current drug discovery strategies for treatment of hepatitis C virus infection

  2011cites this paper